Long-term response to crizotinib in a 17-year-old boy with treatment-naïve ALK-positive non-small-cell lung cancer.

Cancer reports (Hoboken, N.J.) 2022 Mar

filter terms:

Lung cancer is the leading cause of cancer-related death. NSCLC accounts for 80-90% of cases. In young patients, adenocarcinoma is the most frequent histotype and 3-7% expresses the rearrangement of ALK oncogene, sensitive to TKIs. Crizotinib is the first ALK inhibitor approved by the FDA. We present a case of a 17-year-old male with metastatic treatment-naïve ALK-positive adenocarcinoma. He was treated with crizotinib and obtained a prolonged response with PFS of 33 months. Crizotinib can be extremely effective in adolescents with treatment-naïve ALK-positive NSCLC but fail to prevent a central nervous system relapse. Resistance mechanisms need to be investigated. © 2022 The Authors. Cancer Reports published by Wiley Periodicals LLC.

Citation

Giacomina Megaro, Evelina Miele, Gian Paolo Spinelli, Iside Alessi, Giada Del Baldo, Raffaele Cozza, Ida Russo, Maria Debora De Pasquale, Maria Giuseppina Cefalo, Paolo Tomà, Andrea Carai, Valentina Di Ruscio, Maria Antonietta De Ioris, Angela Mastronuzzi. Long-term response to crizotinib in a 17-year-old boy with treatment-naïve ALK-positive non-small-cell lung cancer. Cancer reports (Hoboken, N.J.). 2022 Mar;5(3):e1483